MetLife Investment Management LLC Cuts Stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

MetLife Investment Management LLC lessened its stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 1.5% during the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 134,727 shares of the biopharmaceutical company’s stock after selling 2,098 shares during the quarter. MetLife Investment Management LLC owned approximately 0.11% of Halozyme Therapeutics worth $7,712,000 at the end of the most recent reporting period.

Several other hedge funds have also recently modified their holdings of HALO. GAMMA Investing LLC increased its holdings in Halozyme Therapeutics by 96.6% in the 2nd quarter. GAMMA Investing LLC now owns 517 shares of the biopharmaceutical company’s stock valued at $27,000 after acquiring an additional 254 shares during the last quarter. International Assets Investment Management LLC bought a new position in shares of Halozyme Therapeutics during the 2nd quarter valued at about $33,000. Skandinaviska Enskilda Banken AB publ purchased a new position in shares of Halozyme Therapeutics during the second quarter valued at about $49,000. Toth Financial Advisory Corp bought a new stake in shares of Halozyme Therapeutics in the third quarter worth about $57,000. Finally, FSC Wealth Advisors LLC purchased a new stake in shares of Halozyme Therapeutics in the third quarter worth about $65,000. Hedge funds and other institutional investors own 97.79% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on HALO. Morgan Stanley raised their price target on Halozyme Therapeutics from $59.00 to $64.00 and gave the company an “overweight” rating in a report on Wednesday, August 7th. TD Cowen raised their target price on shares of Halozyme Therapeutics from $59.00 to $65.00 and gave the company a “buy” rating in a report on Wednesday, August 7th. Benchmark restated a “buy” rating and issued a $60.00 price target on shares of Halozyme Therapeutics in a research report on Thursday, August 8th. JMP Securities increased their price objective on shares of Halozyme Therapeutics from $72.00 to $73.00 and gave the company a “market outperform” rating in a research report on Friday, November 1st. Finally, JPMorgan Chase & Co. downgraded shares of Halozyme Therapeutics from an “overweight” rating to a “neutral” rating and boosted their target price for the stock from $52.00 to $57.00 in a report on Thursday, September 19th. Four analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $61.11.

Insider Buying and Selling

In other Halozyme Therapeutics news, CEO Helen Torley sold 10,000 shares of the company’s stock in a transaction on Tuesday, September 10th. The stock was sold at an average price of $59.09, for a total value of $590,900.00. Following the transaction, the chief executive officer now owns 676,744 shares of the company’s stock, valued at $39,988,802.96. This represents a 1.46 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders have sold 60,000 shares of company stock valued at $3,425,000 in the last ninety days. 2.40% of the stock is owned by company insiders.

Halozyme Therapeutics Trading Down 0.6 %

Shares of HALO opened at $48.20 on Friday. Halozyme Therapeutics, Inc. has a twelve month low of $33.15 and a twelve month high of $65.53. The company has a current ratio of 10.36, a quick ratio of 9.15 and a debt-to-equity ratio of 3.32. The company’s fifty day simple moving average is $53.28 and its 200-day simple moving average is $53.67. The company has a market cap of $6.13 billion, a P/E ratio of 15.96, a P/E/G ratio of 0.44 and a beta of 1.29.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.